PURPOSE: Critically ill patients with preserved or increased renal function have been shown to be at risk of underexposure to meropenem. Although many meropenem population pharmacokinetic (PK) models have been published, there is no large prospective population PK study with rich sampling focusing on patients most at risk of suboptimal pharmacokinetic/pharmacodynamic (PK/PD) target attainment. Therefore, the aim of the present study was to evaluate PK/PD target attainment and to perform a thorough covariate screening using population PK modelling of meropenem in septic patients with preserved or increased renal function. PATIENTS AND METHODS: A single-centre prospective observational PK study was performed in the intensive care unit (ICU) of the University Hospitals Leuven. Patients with severe sepsis or septic shock and treated with meropenem in the ICU were screened for inclusion. Patients were excluded if they received renal replacement therapy or had an estimated glomerular filtration rate according to the Chronic Kidney Disease Epidemiology collaboration equation <70 mL/min/1.73m2 on the day of PK sampling. Successful PK/PD target attainment was defined as an unbound meropenem trough concentration above 2 mg/L or 8 mg/L. Population PK modelling was performed with NONMEM7.4. RESULTS: In total, 58 patients were included, contributing 345 plasma samples over 70 dosing intervals. The 2 mg/L and 8 mg/L targets were successfully attained in 46% and 11% of all dosing intervals, respectively. A two-compartment population PK model with linear elimination and interindividual variability on clearance best described meropenem PK. The estimated creatinine clearance according to the Cockcroft-Gault equation was the only covariate retained during population PK analysis. CONCLUSION: This study provided detailed insight into meropenem PK in critically ill patients with preserved or increased renal function. We observed poor PK/PD target attainment, for which renal function was the only significant covariate. TRIAL REGISTRATION: This study is registered at ClinicalTrials.gov (NCT03560557).
PURPOSE: Critically ill patients with preserved or increased renal function have been shown to be at risk of underexposure to meropenem. Although many meropenem population pharmacokinetic (PK) models have been published, there is no large prospective population PK study with rich sampling focusing on patients most at risk of suboptimal pharmacokinetic/pharmacodynamic (PK/PD) target attainment. Therefore, the aim of the present study was to evaluate PK/PD target attainment and to perform a thorough covariate screening using population PK modelling of meropenem in septic patients with preserved or increased renal function. PATIENTS AND METHODS: A single-centre prospective observational PK study was performed in the intensive care unit (ICU) of the University Hospitals Leuven. Patients with severe sepsis or septic shock and treated with meropenem in the ICU were screened for inclusion. Patients were excluded if they received renal replacement therapy or had an estimated glomerular filtration rate according to the Chronic Kidney Disease Epidemiology collaboration equation <70 mL/min/1.73m2 on the day of PK sampling. Successful PK/PD target attainment was defined as an unbound meropenem trough concentration above 2 mg/L or 8 mg/L. Population PK modelling was performed with NONMEM7.4. RESULTS: In total, 58 patients were included, contributing 345 plasma samples over 70 dosing intervals. The 2 mg/L and 8 mg/L targets were successfully attained in 46% and 11% of all dosing intervals, respectively. A two-compartment population PK model with linear elimination and interindividual variability on clearance best described meropenem PK. The estimated creatinine clearance according to the Cockcroft-Gault equation was the only covariate retained during population PK analysis. CONCLUSION: This study provided detailed insight into meropenem PK in critically ill patients with preserved or increased renal function. We observed poor PK/PD target attainment, for which renal function was the only significant covariate. TRIAL REGISTRATION: This study is registered at ClinicalTrials.gov (NCT03560557).
Authors: Danny Tsai; Penelope Stewart; Rajendra Goud; Stephen Gourley; Saliya Hewagama; Sushena Krishnaswamy; Steven C Wallis; Jeffrey Lipman; Jason A Roberts Journal: Int J Antimicrob Agents Date: 2016-09-29 Impact factor: 5.283
Authors: Alexis Tabah; Jan De Waele; Jeffrey Lipman; Jean Ralph Zahar; Menino Osbert Cotta; Greg Barton; Jean-Francois Timsit; Jason A Roberts Journal: J Antimicrob Chemother Date: 2015-07-13 Impact factor: 5.790
Authors: Mieke Carlier; Alexander Dumoulin; Alexander Janssen; Sven Picavet; Steve Vanthuyne; Ria Van Eynde; Raymond Vanholder; Joris Delanghe; Gert De Schoenmakere; Jan J De Waele; Eric A J Hoste Journal: Intensive Care Med Date: 2015-01-27 Impact factor: 17.440
Authors: Abdulaziz S Alobaid; Steven C Wallis; Paul Jarrett; Therese Starr; Janine Stuart; Melissa Lassig-Smith; Jenny Lisette Ordóñez Mejia; Michael S Roberts; Jeffrey Lipman; Jason A Roberts Journal: Antimicrob Agents Chemother Date: 2016-07-22 Impact factor: 5.191
Authors: Jason A Roberts; Carl M J Kirkpatrick; Michael S Roberts; Thomas A Robertson; Andrew J Dalley; Jeffrey Lipman Journal: J Antimicrob Chemother Date: 2009-04-27 Impact factor: 5.790
Authors: R P Dellinger; Mitchell M Levy; Andrew Rhodes; Djillali Annane; Herwig Gerlach; Steven M Opal; Jonathan E Sevransky; Charles L Sprung; Ivor S Douglas; Roman Jaeschke; Tiffany M Osborn; Mark E Nunnally; Sean R Townsend; Konrad Reinhart; Ruth M Kleinpell; Derek C Angus; Clifford S Deutschman; Flavia R Machado; Gordon D Rubenfeld; Steven Webb; Richard J Beale; Jean-Louis Vincent; Rui Moreno Journal: Intensive Care Med Date: 2013-01-30 Impact factor: 17.440
Authors: Jason A Roberts; Sanjoy K Paul; Murat Akova; Matteo Bassetti; Jan J De Waele; George Dimopoulos; Kirsi-Maija Kaukonen; Despoina Koulenti; Claude Martin; Philippe Montravers; Jordi Rello; Andrew Rhodes; Therese Starr; Steven C Wallis; Jeffrey Lipman Journal: Clin Infect Dis Date: 2014-01-14 Impact factor: 9.079